HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Luwy Musey Selected Research

Conjugate Vaccines

7/2023Safety and Tolerability of V114 Pneumococcal Vaccine in Infants: A Phase 3 Study.
10/2022A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants, children, and adolescents (PNEU-PLAN).
3/2022Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18-49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY).
10/2021Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Luwy Musey Research Topics

Disease

11Pneumococcal Infections
12/2023 - 01/2016
4Pain (Aches)
01/2023 - 10/2021
4Infections
12/2019 - 07/2003
2Fatigue
01/2023 - 03/2022
1Graft vs Host Disease (Graft-Versus-Host Disease)
10/2023
1Fever (Fevers)
07/2023
1Injection Site Reaction
01/2023
1Diphtheria
01/2023
1Hepatitis B
01/2023
1Hypersensitivity (Allergy)
01/2023
1Tetanus
01/2023
1Whooping Cough (Pertussis)
01/2023
1Myalgia
01/2023
1Pneumococcal Pneumonia
01/2021
1Spontaneous Abortion (Miscarriage)
12/2019
1Virus Diseases (Viral Diseases)
12/2019
1Measles
01/2016
1Rubella (German Measles)
01/2016
1Mumps
01/2016
1Neoplasms (Cancer)
05/2009

Drug/Important Bio-Agent (IBA)

923-valent pneumococcal capsular polysaccharide vaccineIBA
12/2023 - 01/2016
9VaccinesIBA
07/2023 - 07/2003
4Conjugate VaccinesIBA
07/2023 - 10/2021
4Pneumococcal Vaccines (Pneumococcal Polysaccharide Vaccine)IBA
01/2023 - 01/2021
2Polysaccharides (Glycans)IBA
01/2023 - 01/2021
2AntigensIBA
05/2009 - 09/2003
1gamma- hydroxy- gamma- ethyl- gamma- phenylbutyramide (HEPB)IBA
01/2023
1Cytomegalovirus VaccinesIBA
12/2019
1Viral AntigensIBA
12/2019
1AntibodiesIBA
12/2019
1Neutralizing AntibodiesIBA
01/2019
1ImmunosorbentsIBA
01/2016
1EnzymesIBA
01/2016
1Rubella VaccineIBA
01/2016

Therapy/Procedure

1Therapeutics
05/2009
1Immunotherapy
05/2009